Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX

Bamco Inc. NY lifted its holdings in Arcellx, Inc. (NASDAQ:ACLX) by 6.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 550,236 shares of the company’s stock after acquiring an additional 32,227 shares during the quarter. Bamco Inc. NY owned approximately 0.95% of Arcellx worth $45,174,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Decheng Capital LLC increased its holdings in Arcellx by 995.2% during the 2nd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $36,060,000 after purchasing an additional 497,609 shares in the last quarter. American Century Companies Inc. boosted its stake in Arcellx by 694.3% in the second quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after purchasing an additional 377,145 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Arcellx by 15.2% during the second quarter. Vestal Point Capital LP now owns 2,750,000 shares of the company’s stock worth $181,088,000 after purchasing an additional 362,280 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Arcellx by 42.9% during the second quarter. JPMorgan Chase & Co. now owns 976,968 shares of the company’s stock worth $64,333,000 after purchasing an additional 293,387 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its stake in shares of Arcellx by 44.3% in the third quarter. Schonfeld Strategic Advisors LLC now owns 500,315 shares of the company’s stock valued at $41,076,000 after buying an additional 153,587 shares in the last quarter. 96.03% of the stock is currently owned by institutional investors.

Insider Activity at Arcellx

In related news, insider Rami Elghandour sold 89,916 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider directly owned 276,051 shares of the company’s stock, valued at $31,447,729.92. The trade was a 24.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Christopher Heery sold 5,882 shares of the stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the completion of the transaction, the insider owned 23,749 shares in the company, valued at $1,627,043.99. This represents a 19.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 109,366 shares of company stock valued at $11,526,708. 8.35% of the stock is owned by corporate insiders.

Arcellx Stock Up 0.1%

Arcellx stock opened at $114.39 on Monday. The business’s 50-day simple moving average is $81.66 and its 200 day simple moving average is $79.32. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of -28.11 and a beta of 0.22. Arcellx, Inc. has a 12-month low of $47.86 and a 12-month high of $114.80.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, hitting the consensus estimate of ($1.01). Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%.The firm had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $13.40 million. As a group, sell-side analysts expect that Arcellx, Inc. will post -1.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ACLX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. HC Wainwright cut shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price objective for the company. in a research report on Monday, February 23rd. Citigroup downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $110.00 to $115.00 in a research note on Tuesday, February 24th. Wells Fargo & Company lowered shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 target price on the stock. in a research report on Monday, February 23rd. Finally, Robert W. Baird reissued a “neutral” rating and set a $115.00 price target (up from $106.00) on shares of Arcellx in a research note on Monday, February 23rd. One analyst has rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $111.87.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.